Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder Studies

Cingulate Inc CING plans to initiate Phase 3 studies for CTx-1301 for Attention Deficit/Hyperactivity Disorder (ADHD) in 2022.

  • ADHD is a chronic neurobiological and developmental disorder.
  • The planned studies include a fixed-dose pediatric & adolescent safety and efficacy study, a dose-optimization study extension, and a pediatric safety & efficacy study to assess the onset and duration of efficacy. 
  • Specifically, the pivotal, fixed-dose study will begin in Q2 of 2022. 
  • These studies are instrumental for the filing of the New Drug Application to the FDA, expected in 2H of 2023.
  • Based on feedback from the FDA regarding the CTx-1301 initial Pediatric Study Plan and longstanding guidance on the 505(b)(2) pathway, Cingulate has accelerated its study timeline, with a strong likelihood of reducing capital requirements by condensing the number and design of studies, therefore potentially reducing its time to approval.
  • Price Action: CING shares are down 5.46% at $1.73 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!